The Lancet Oncology
Fecha de publicación: 2 April 2019
Autores: Philipp Kickingereder, MD., Fabian Isensee, MSc., Irada Tursunova, MD., Jens Petersen, MSc., Ulf Neuberger, MD., David Bonekamp, MD., et al.
Background: The Response Assessment in Neuro-Oncology (RANO) criteria and requirements for a uniform protocol have been introduced to standardise assessment of MRI scans in both clinical trials and clinical practice. However, these criteria mainly rely on manual two-dimensional measurements of contrast-enhancing (CE) target lesions and thus restrict both reliability and accurate assessment of tumour burden and treatment response.Leer más